Globus Medical, Inc. $GMED is Anchor Capital Advisors LLC’s 10th Largest Position

Anchor Capital Advisors LLC decreased its holdings in Globus Medical, Inc. (NYSE:GMED) by 13.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 695,352 shares of the medical device company’s stock after selling 104,930 shares during the period. Globus Medical comprises approximately 1.8% of Anchor Capital Advisors LLC’s holdings, making the stock its 10th largest holding. Anchor Capital Advisors LLC owned approximately 0.52% of Globus Medical worth $60,711,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of GMED. William Blair Investment Management LLC lifted its holdings in Globus Medical by 17.2% during the third quarter. William Blair Investment Management LLC now owns 2,819,165 shares of the medical device company’s stock worth $161,454,000 after buying an additional 414,134 shares during the period. ANTIPODES PARTNERS Ltd boosted its position in Globus Medical by 49,020.3% during the third quarter. ANTIPODES PARTNERS Ltd now owns 891,043 shares of the medical device company’s stock valued at $51,034,000 after purchasing an additional 889,229 shares in the last quarter. Foresight Group Ltd Liability Partnership boosted its position in Globus Medical by 160.7% during the third quarter. Foresight Group Ltd Liability Partnership now owns 421,541 shares of the medical device company’s stock valued at $24,142,000 after purchasing an additional 259,870 shares in the last quarter. Annex Advisory Services LLC purchased a new position in Globus Medical in the fourth quarter valued at about $20,572,000. Finally, Kingdon Capital Management L.L.C. raised its holdings in Globus Medical by 51.6% in the third quarter. Kingdon Capital Management L.L.C. now owns 257,650 shares of the medical device company’s stock worth $14,756,000 after purchasing an additional 87,650 shares in the last quarter. 95.16% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on the stock. Zacks Research upgraded shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Needham & Company LLC upped their price objective on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a report on Friday, May 8th. Truist Financial set a $115.00 price target on Globus Medical in a research report on Wednesday, February 25th. Wall Street Zen lowered shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 9th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a research note on Wednesday, April 15th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, Globus Medical has a consensus rating of “Moderate Buy” and a consensus price target of $106.36.

Globus Medical Price Performance

NYSE GMED opened at $78.28 on Wednesday. The firm’s 50-day moving average is $86.88 and its two-hundred day moving average is $88.39. Globus Medical, Inc. has a 12 month low of $51.79 and a 12 month high of $101.40. The stock has a market capitalization of $10.63 billion, a P/E ratio of 18.20, a PEG ratio of 1.65 and a beta of 0.95.

Globus Medical (NYSE:GMED) last posted its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 EPS for the quarter, beating the consensus estimate of $0.92 by $0.20. The business had revenue of $759.85 million during the quarter, compared to analyst estimates of $740.35 million. Globus Medical had a net margin of 18.92% and a return on equity of 13.46%. The business’s revenue for the quarter was up 27.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, analysts anticipate that Globus Medical, Inc. will post 4.74 EPS for the current year.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.